Frontiers in Pharmacology | Gastrointestinal and Hepatic Pharmacology

Review

Published on 08 May 2025

Knowledge landscape of macrophage research in liver fibrosis: a bibliometric review of the literature from WoSCC

in Gastrointestinal and Hepatic Pharmacology

Yanbo Li
Zhengmin Cao
Yanping Lu
Chao Lei
Wenliang Lyu

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1571879

101 views

Original Research

Published on 08 May 2025

Metformin improves intestinal ischemia-reperfusion injury by reducing the formation of mitochondrial associated endoplasmic reticulum membranes (MAMs) and inhibiting ferroptosis in intestinal cells

in Gastrointestinal and Hepatic Pharmacology

Xu Zhao
Likun Yan
Lifei Tian
Xiaolong Zhang
Ruiting Liu
Zeyu Li

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1581085

104 views

Original Research

Published on 06 May 2025

Pachymic acid alleviates metabolic dysfunction-associated steatotic liver disease by inhibiting ferroptosis through PPARα

in Gastrointestinal and Hepatic Pharmacology

Guilin Ren
Yiyou Lin
Jiannan Qiu
Congcong Zhang
Lin Chen
Linwensi Zhu
Xiaohui Fan
Xiaobing Dou
Qingsheng Liu

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1554850

234 views

Original Research

Accepted on 30 Apr 2025

Remogliflozin Protective Role against Experimental Liver Fibrosis by Activating AMPK/SIRT1/Nrf2 and Suppressing NF-κB Pathways

in Gastrointestinal and Hepatic Pharmacology

Naif ALSuhaymi
Mahdi Alsugoor
Aya Shokry
Hany Moawad Fayed
Bassim Mohamed
Sherif Afifi
Tuba Esatbeyoglu
Reda Korany
Marawan Elbaset

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1586231

Systematic Review

Published on 30 Apr 2025

Assessing the therapeutic potential of rutin in alleviating symptoms of inflammatory bowel disease: a meta-analysis

in Gastrointestinal and Hepatic Pharmacology

Zhenkai Zou
Fanglian Zhang
Zhigang Pan
Jinyao Xu
Xuanyi Li
Xiangjun Sun
Xufeng Wang
Feng Qin
Abulikemu Abulizi
Qian Chen

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1539469

399 views

Original Research

Published on 30 Apr 2025

Albiflorin inhibits inflammation to improve liver fibrosis by targeting the CXCL12/CXCR4 axis in mice

in Gastrointestinal and Hepatic Pharmacology

Lingjie Meng
Huijing Lv
Anli Liu
Qian Cao
Xinyi Du
Chengjin Li
Qinggui Li
Qingqing Luo
Yi Xiao

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1577201

595 views

Original Research

Published on 30 Apr 2025

Resveratrol targeting MDM2/P53/PUMA axis to inhibit colonocyte apoptosis in DSS-induced ulcerative colitis mice

in Gastrointestinal and Hepatic Pharmacology

Rui Tang
Ling Jiang
Quan Ji
Pengyuan Kang
Yuan Liu
Pengyu Miao
Xiaofan Xu
Mingxi Tang

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1572906

269 views

Review

Accepted on 29 Apr 2025

Pharmacological potential of endocannabinoid and endocannabinoid-like compounds in protecting intestinal structure and metabolism under high-fat conditions

in Gastrointestinal and Hepatic Pharmacology

Francesco Vari
Ilaria Serra
Marzia Friuli
Viviana Cavallo
Nicola Gammaldi
Daniele Vergara
Michel Salzet
Anna Maria Giudetti

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1567543

Original Research

Published on 29 Apr 2025

Proton pump inhibitors use and risk of type 2 diabetes mellitus: correlation analysis, prediction model construction, and key genes identification

in Gastrointestinal and Hepatic Pharmacology

Cuilv Liang
Yin Zhang

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1580090

426 views

Mini Review

Accepted on 28 Apr 2025

Effect of Diquat on Gut Health: Molecular Mechanisms, Toxic Effects, and Protective Strategies

in Gastrointestinal and Hepatic Pharmacology

Cheng He
Guorong Cai
Yingmao Jia
Rong Jiang
Xiaolan Wei
Ning Tao

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1562182

Review

Published on 28 Apr 2025

Gastrointestinal injury in cardiopulmonary bypass: current insights and future directions

in Gastrointestinal and Hepatic Pharmacology

Qi-Long Mao
Zi-Hang Yu
Liang Nie
Fei-Xiang Wang
Yu-Hui Dong
Xiao-Fei Qi

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1542995

208 views

Original Research

Published on 28 Apr 2025

Resveratrol and N-acetylcystein reduce hepatic steatosis but enhance initiation and progression of hepatocellular carcinoma by inhibiting GST-pi-MAPK axis in mice

in Gastrointestinal and Hepatic Pharmacology

Mi Zhang
Weigang Yuan
Chun Li
Chanyuan Chen
Xiang Liu
Zhilu Ma
Yifei Xiang
Guisha Chen
Chunxu Wang
Lei Li

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1574039

290 views

Systematic Review

Published on 28 Apr 2025

Efficacy and safety of IL-23 p19 inhibitors in the treatment for inflammatory bowel disease: a systematic review and meta-analysis

in Gastrointestinal and Hepatic Pharmacology

Shuhan Wang
Hui Sun
Qian Wang
Han Xiao

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1490667

369 views

Review

Published on 28 Apr 2025

The role of hepatic sinusoidal microenvironment in NASH: pathogenesis, animal models, and therapeutic prospects

in Gastrointestinal and Hepatic Pharmacology

Wanying Tan
Jiangting Deng
Lingjun Qi
Zhenghuai Tan

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1467950

194 views

Original Research

Published on 25 Apr 2025

Macrophage PKM2 depletion ameliorates hepatic inflammation and acute liver injury in mice

in Gastrointestinal and Hepatic Pharmacology

Ziwei Kang
Ruoyan Xie
Yiming Cui
Zhiwei Chen
Jincheng Li
Jinyu Lv
Weijia Ye
Peixin Zhao
Keke Zhang
Jian Hong

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1546045

346 views

Original Research

Accepted on 24 Apr 2025

First-Line Treatment of Hepatocellular Carcinoma: A Propensity-Matched Analysis of Tyrosine Kinase Inhibitors Combined with TACE, with or without PD-1 Inhibitors

in Gastrointestinal and Hepatic Pharmacology

Yanjun Shen
Yawen Xu
Ying Teng
Xiaoyan Ding
Jinglong Chen

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1533471

158 views